Achillion’s hep C drug remains in limbo 2Achillion Pharmaceuticals recently announced that the US Food and Drug Administration (FDA) has decided to maintain its clinical hold on sovaprevir, the company’s flagship treatment for hepatitis C.

The recent clinical data submitted by Achillion sought to address the issues previously flagged up by the FDA but the administration has decided that removal of the clinical hold is not warranted.

Milind Deshpande, chief exeuctive, said: “While we are disappointed that we were not able to resolve the clinical hold at this time despite having addressed all the issues, we believe the breadth of our portfolio allows to quickly advance other all oral combination regimens for the treatment of hepatitis C virus”.

Read more on our coverage of the story here:




Add a comment

Your email address will not be published. Required fields are marked *